- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05999877
PICAROS - Acalabrutinib RWE på 1L CLL i Spanien (PICAROS)
Ikke-interventionel kohorteundersøgelse af patienter, der tidligere er ubehandlet eller førstegenerations BTKi-intolerante med kronisk lymfatisk leukæmi, der beskriver førstelinjebrugen af acalabrutinib og dets virkelige resultater i Spanien: PICAROS-undersøgelsen
This is a multicenter non-interventional study (NIS) of patients with CLL treated with first-line acalabrutinib according to routine clinical practice in Spain. It included an initial cohort of patients who initiated treat-to-progression acalabrutinib for the first time within the year before the first site initiation visit, both for previously untreated CLL and after switching in first line from another BTK inhibitor due to intolerance in absence of progression (cohort 1). This cohort is complemented with the addition of another regarding the first-line fixed-duration acalabrutinib use with venetoclax in routine practice (cohort 2).
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
This is a multicenter, non-interventional study (NIS) based on ambispective (including retrospective and/or prospective) real-world data collection of patients with CLL who received treatment with acalabrutinib for the first time in Spain.
It included an initial cohort of patients who initiated treat-to-progression acalabrutinib for the first time within the year before the first site initiation visit, both for previously untreated CLL and after switching in first line from another BTK inhibitor due to intolerance in absence of progression (cohort 1). This cohort is complemented with the addition of another regarding the first-line fixed-duration acalabrutinib use with venetoclax in routine practice (cohort 2).
For the cohort 1, the start of acalabrutinib treatment (index date) was prior to the first site initiation visit. For both cohorts 1 and 2, the clinical decision of starting patient on acalabrutinib has to independently occur prior to the patient inclusion into this study. Patients' eligibility for study inclusion is regardless of their current status of acalabrutinib therapy, for example, patients already deceased or discontinued therapy are still eligible to be included into this study. Patient data will be collected both retrospectively and/or prospectively up to approximately 32 months from the first site initiation visit for cohort 1, and approximately 25 months after the inclusion of the last patient in the cohort 2. For patients who received acalabrutinib therapy and have deceased, only retrospective medical chart review will be conducted.
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiekontakt
- Navn: AstraZeneca Clinical Study Information Center
- Telefonnummer: 1-877-240-9479
- E-mail: information.center@astrazeneca.com
Studiesteder
-
-
Andalusia
-
Almería, Andalusia, Spanien, 4009
- Rekruttering
- Research Site
-
Córdoba, Andalusia, Spanien, 14004
- Rekruttering
- Research Site
-
Granada, Andalusia, Spanien, 18014
- Rekruttering
- Research Site
-
Jaén, Andalusia, Spanien, 23007
- Aktiv, ikke rekrutterende
- Research Site
-
Marbella, Andalusia, Spanien, 29603
- Aktiv, ikke rekrutterende
- Research Site
-
Málaga, Andalusia, Spanien, 29010
- Aktiv, ikke rekrutterende
- Research Site
-
Seville, Andalusia, Spanien, 41013
- Rekruttering
- Research Site
-
-
Aragon
-
Zaragoza, Aragon, Spanien, 50009
- Rekruttering
- Research Site
-
Zaragoza, Aragon, Spanien, 50009
- Aktiv, ikke rekrutterende
- Research Site
-
-
Balearic Islands
-
Palma de Mallorca, Balearic Islands, Spanien, 7010
- Aktiv, ikke rekrutterende
- Research Site
-
Palma de Mallorca, Balearic Islands, Spanien, 7198
- Aktiv, ikke rekrutterende
- Research Site
-
-
Basque Country
-
Donostia / San Sebastian, Basque Country, Spanien, 20014
- Trukket tilbage
- Research Site
-
Galdakao, Basque Country, Spanien, 48960
- Trukket tilbage
- Research Site
-
-
Canary Islands
-
Las Palmas de Gran Canaria, Canary Islands, Spanien, 35016
- Aktiv, ikke rekrutterende
- Research Site
-
Las Palmas de Gran Canaria, Canary Islands, Spanien, 35019
- Aktiv, ikke rekrutterende
- Research Site
-
San Cristóbal de La Laguna, Canary Islands, Spanien, 38320
- Rekruttering
- Research Site
-
-
Cantabria
-
Santander, Cantabria, Spanien, 39008
- Aktiv, ikke rekrutterende
- Research Site
-
-
Castille and León
-
Salamanca, Castille and León, Spanien, 37007
- Aktiv, ikke rekrutterende
- Research Site
-
Segovia, Castille and León, Spanien, 40002
- Aktiv, ikke rekrutterende
- Research Site
-
Valladolid, Castille and León, Spanien, 47003
- Aktiv, ikke rekrutterende
- Research Site
-
Valladolid, Castille and León, Spanien, 47012
- Aktiv, ikke rekrutterende
- Research Site
-
-
Castille-La Mancha
-
Guadalajara, Castille-La Mancha, Spanien, 19002
- Rekruttering
- Research Site
-
Toledo, Castille-La Mancha, Spanien, 45004
- Aktiv, ikke rekrutterende
- Research Site
-
-
Catalonia
-
Barcelona, Catalonia, Spanien, 8003
- Aktiv, ikke rekrutterende
- Research Site
-
Barcelona, Catalonia, Spanien, 8025
- Aktiv, ikke rekrutterende
- Research Site
-
Barcelona, Catalonia, Spanien, 8035
- Aktiv, ikke rekrutterende
- Research Site
-
Barcelona, Catalonia, Spanien, 8036
- Aktiv, ikke rekrutterende
- Research Site
-
Granollers, Catalonia, Spanien, 8402
- Aktiv, ikke rekrutterende
- Research Site
-
L'Hospitalet de Llobregat, Catalonia, Spanien, 8908
- Aktiv, ikke rekrutterende
- Research Site
-
Lleida, Catalonia, Spanien, 25198
- Aktiv, ikke rekrutterende
- Research Site
-
Terrassa, Catalonia, Spanien, 8221
- Aktiv, ikke rekrutterende
- Research Site
-
-
Galicia
-
Ourense, Galicia, Spanien, 32005
- Rekruttering
- Research Site
-
Santiago de Compostela, Galicia, Spanien, 15706
- Aktiv, ikke rekrutterende
- Research Site
-
Vigo, Galicia, Spanien, 36312
- Rekruttering
- Research Site
-
-
Madrid
-
Madrid, Madrid, Spanien, 28006
- Rekruttering
- Research Site
-
Madrid, Madrid, Spanien, 28031
- Aktiv, ikke rekrutterende
- Research Site
-
Madrid, Madrid, Spanien, 28034
- Aktiv, ikke rekrutterende
- Research Site
-
Madrid, Madrid, Spanien, 28905
- Aktiv, ikke rekrutterende
- Research Site
-
Madrid, Madrid, Spanien, 28911
- Aktiv, ikke rekrutterende
- Research Site
-
Madrid, Madrid, Spanien, 28040
- Rekruttering
- Research Site
-
Madrid, Madrid, Spanien, 28041
- Rekruttering
- Research Site
-
Madrid, Madrid, Spanien, 28046
- Rekruttering
- Research Site
-
Majadahonda, Madrid, Spanien, 28222
- Aktiv, ikke rekrutterende
- Research Site
-
-
Murcia
-
El Palmar, Murcia, Spanien, 30120
- Aktiv, ikke rekrutterende
- Research Site
-
Murcia, Murcia, Spanien, 30008
- Rekruttering
- Research Site
-
-
Principality of Asturias
-
Oviedo, Principality of Asturias, Spanien, 33011
- Aktiv, ikke rekrutterende
- Research Site
-
-
Valencia
-
Alicante, Valencia, Spanien, 3010
- Rekruttering
- Research Site
-
Valencia, Valencia, Spanien, 46010
- Aktiv, ikke rekrutterende
- Research Site
-
Valencia, Valencia, Spanien, 46014
- Aktiv, ikke rekrutterende
- Research Site
-
Valencia, Valencia, Spanien, 46026
- Aktiv, ikke rekrutterende
- Research Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
The study aims to include approximately 315 patients in the cohort 1 and 103 patients in the cohort 2 who started acalabrutinib for the first time for the treatment of their CLL. To minimize selection biases, all patients (alive or deceased) identified on acalabrutinib will be eligible for inclusion into the study. These patients will be included from approximately 50 hospitals distributed throughout Spain.
Beskrivelse
Inclusion Criteria:
- Age ≥18 years old at starting acalabrutinib treatment.
- Diagnosis of CLL.
- Start of acalabrutinib treatment (index date) as per the CLL SmPC:
- in treatment-naïve CLL patients or those switching in first-line between first-generation BTK inhibitor to acalabrutinib due to intolerance in absence of progression according to routine clinical practice within the year before the first site initiation visit (cohort 1).
- in treatment-naïve CLL patients for the fixed-duration treatment combination of acalabrutinib plus venetoclax (with or without obinutuzumab) according to routine clinical practice from the EMA approval (i.e., 2 June 2025) (cohort 2).
Decision to administer acalabrutinib must be made and documented prior to inclusion into the study and must follow local clinical practice.
- Informed consent (for alive patients).
Exclusion Criteria:
- Enrolled in any clinical trial during acalabrutinib treatment.
- Patients who are unable to understand the study and its questionnaires due to insufficient knowledge of the Spanish language or their health status.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: OTHER
Kohorter og interventioner
Gruppe / kohorte |
|---|
|
Cohort 1
Patients who initiated treat-to-progression acalabrutinib for the first time within the year before the first site initiation visit as per routine clinical practice, both for previously untreated CLL and after switching in first line from another BTK inhibitor due to intolerance in absence of progression. |
|
Cohort 2
Patients with first-line fixed-duration acalabrutinib use with venetoclax in routine clinical practice. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of patients on acalabrutinib therapy at 24 months after treatment initiation (cohort 1).
Tidsramme: 24 months after treatment initiation (cohort 1).
|
Proportion of patients on acalabrutinib therapy at 24 months after treatment initiation (cohort 1). In addition to this outcome measured in the overall cohort, it will also be assessed by the following factors:
|
24 months after treatment initiation (cohort 1).
|
|
Real-world overall response rate (rwORR) achieved until the end of the observational period for first-line fixed duration acalabrutinib therapy (cohort 2)
Tidsramme: From fixed-duration acalabrutinib start to the start date of a subsequent line therapy or study end date (cohort 2), assessed up to 25 months after the inclusion of the last patient in the cohort 2.
|
rwORR (i.e., the proportion of patients that achieved complete or partial response) achieved until the end of the observational period for first-line fixed-duration acalabrutinib therapy as assessed by the treating physician (cohort 2). Complete response may include complete response, complete response with incomplete marrow recovery, or unconfirmed complete response (marrow biopsy not performed). Partial response may include partial response, or partial response with lymphocytosis. The rwORR will be assessed by the treating physician in routine clinical practice, including the use or not of the 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria. The end of observational period for first-line fixed-duration combinations of acalabrutinib is defined as the start date of a subsequent line therapy or study end date, whichever comes first. |
From fixed-duration acalabrutinib start to the start date of a subsequent line therapy or study end date (cohort 2), assessed up to 25 months after the inclusion of the last patient in the cohort 2.
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Acalabrutinib±venetoclax doses (cohorts 1 and 2).
Tidsramme: At start date and subsequent dose adjustments during acalabrutinib±venetoclax administration assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
|
Acalabrutinib±venetoclax doses (e.g., starting does and dose adjustments), overall (cohorts 1 and 2) and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only). In cohort 2, doses (e.g., starting dose, dose adjustments, maximum dose achieved) and reasons for changes within the acalabrutinib±venetoclax fixed-duration regimen will also be described globally and for each drug separately, as well as the time to reach the maximal dose. |
At start date and subsequent dose adjustments during acalabrutinib±venetoclax administration assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
|
|
Patients with acalabrutinib±venetoclax dose adjustments (n, %), temporary interruptions (n, %), and permanent discontinuations (n, %) (cohorts 1 and 2).
Tidsramme: From acalabrutinib±venetoclax start to acalabrutinib±venetoclax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
|
Acalabrutinib±venetoclax dose adjustments, temporary interruptions, and permanent discontinuations, overall (cohorts 1 and 2) and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only). In patients with regimen modifications within cohort 2, the proportion of patients with these regimen modifications and the time from treatment initiation to the regimen modification within same line therapy prior to progression (e.g., treatment duration and number of cycles prior to the modification, and reason for the modification). In cohort 2, temporary interruptions, permanent discontinuations, and their reasons for changes within the acalabrutinib±venetoclax fixed-duration regimen will also be described globally and for each drug separately, as well as the proportion of patients requiring dose reductions after achieving maximum dose. |
From acalabrutinib±venetoclax start to acalabrutinib±venetoclax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
|
|
Treatment duration in months (cohorts 1 and 2).
Tidsramme: From acalabrutinib±venetoclax start to acalabrutinib±venetoclax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
|
Treatment duration (cohorts 1 and 2), overall and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only). In cohort 2, also median number of completed cycles and the proportion of patients who complete 14 cycles. Baseline patient characteristics associated with treatment duration in multivariate analyses, overall (cohorts 1 and 2) and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only). |
From acalabrutinib±venetoclax start to acalabrutinib±venetoclax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
|
|
Treatment adherence according to the percentage of days covered (PDC) while receiving acalabrutinib (cohort 1).
Tidsramme: From acalabrutinib start to acalabrutinib end, assessed up to 32 months of prospective study follow-up (cohort 1).
|
Treatment adherence according to the percentage of days covered (PDC) while receiving acalabrutinib, overall and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1). The PDC will be based on data available on acalabrutinib treatment in pharmacy records, and defined as the percentage of days a patient has the medication available in a given period of time: PDC (%)=(No.days covered)/(No.days of interest)×100 |
From acalabrutinib start to acalabrutinib end, assessed up to 32 months of prospective study follow-up (cohort 1).
|
|
TTNT (i.e., the time from the date of first dose of acalabrutinib to the first dose of the next treatment for CLL, or death from any cause) (cohorts 1 and 2).
Tidsramme: From the date of first dose of acalabrutinib to first dose of next CLL treatment or death, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
|
TTNT (i.e., the time from the date of first dose of acalabrutinib to the first dose of the next treatment for CLL, or death from any cause [i.e. deaths are not censored]), overall (cohorts 1 and 2) and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only). |
From the date of first dose of acalabrutinib to first dose of next CLL treatment or death, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
|
|
OS (i.e., the time from the date of first dose of acalabrutinib to death from any cause) (cohorts 1 and 2).
Tidsramme: From the date of first dose of acalabrutinib to death, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
|
OS (i.e., the time from the date of first dose of acalabrutinib to death from any cause), overall (cohorts 1 and 2) and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only). |
From the date of first dose of acalabrutinib to death, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
|
|
Adverse events that lead to acalabrutinib±venetoclax dose changes, temporary interruptions, or permanent discontinuation; that are considered serious during acalabrutinib±venetoclax treatment; and events of clinical interest (cohorts 1 and 2).
Tidsramme: From acalabrutinib±venetoclax start to acalabrutinib±venetoxlax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
|
Adverse events that lead to acalabrutinib±venetoclax dose changes, temporary interruptions, or permanent discontinuation. Adverse events that are considered serious (including fatal events) during acalabrutinib±venetoclax treatment, globally and treatment related (when available). Events of clinical interest (atrial fibrillation, hypertension, bleeding, infections, ventricular arrhythmias, hepatotoxicity, secondary primary malignancies, cytopenia, and pneumonitis) during acalabrutinib treatment, globally and treatment related (when available). They will be described overall (cohorts 1 and 2) and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only). |
From acalabrutinib±venetoclax start to acalabrutinib±venetoxlax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Patologiske processer
- Neoplasmer
- Kronisk sygdom
- Sygdomsegenskaber
- Sygdomme i immunsystemet
- Neoplasmer efter histologisk type
- Hæmatologiske sygdomme
- Lymfesygdomme
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Leukæmi, B-celle
- Leukæmi, lymfoid
- Leukæmi
- Patologiske tilstande, tegn og symptomer
- Hemiske og lymfatiske sygdomme
- Leukæmi, lymfatisk, kronisk, B-celle
Andre undersøgelses-id-numre
- D8221R00003
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
IPD-delingstidsramme
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD-delingsadgangskriterier
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .